Columbia Sportswear Co
Change company Symbol lookup
Select an option...
COLM Columbia Sportswear Co
HEAR Turtle Beach Corp
GWPH GW Pharmaceuticals PLC
GTBIF Green Thumb Industries Inc
GOOG Alphabet Inc
GILD Gilead Sciences Inc
GBLX GB Sciences Inc
FANG Diamondback Energy Inc
EOG EOG Resources Inc
DVN Devon Energy Corp
Go

Consumer Discretionary : Textiles, Apparel & Luxury Goods | Mid Cap Blend
Company profile

Columbia Sportswear Company is an apparel and footwear company. The Company designs, sources, markets and distributes outdoor lifestyle apparel, footwear, accessories and equipment under the Columbia, Mountain Hardwear, Sorel, prAna and other brands. Its geographic segments are the United States, Latin America and Asia Pacific (LAAP), Europe, Middle East and Africa (EMEA), and Canada. The Company develops and manages its merchandise in categories, including apparel, accessories and equipment, and footwear. It distributes its products through a mix of wholesale distribution channels, its own direct-to-consumer channels (retail stores and e-commerce), independent distributors and licensees. As of December 31, 2016, its products were sold in approximately 90 countries. In 59 of those countries, it sells to independent distributors to whom it has granted distribution rights. Contract manufacturers located outside the United States manufacture all of its products.

Closing Price
$66.18
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
472,664
0

Sientra Reports Fourth Quarter and Full Year 2019 Financial Results

4:06 pm ET March 11, 2020 (Globe Newswire) Print

Achieves Record Fourth Quarter Net Sales and Strong Growth Across Both Business Segments

Well-Capitalized Balance Sheet Provides Enhanced Flexibility to Execute on Strategic Initiatives

Q4 and Full Year 2019 Highlights:

-- Record Q4 total net sales of $23.2 million, growth of 22% year-over-year

-- Breast Products Q4 net sales of $12.8 million, growth of 22% year-over-year

-- Record miraDry Q4 net sales of $10.4 million, growth of 22% year-over-year

-- Record full year 2019 consolidated net sales of $83.7 million, growth of 23% year-over-year

Sientra, Inc. (NASDAQ: SIEN) ("Sientra" or the "Company"), a diversified medical aesthetics company, today announced its financial results for the fourth quarter and full year ended December 31, 2019.

Jeff Nugent, Sientra's Chairman and Chief Executive Officer, said, "2019 was a pivotal year of growth and strategic transformation for Sientra. We achieved important vertical integration through our fourth-quarter acquisition of OPUS breast implant manufacturing operations from Vesta, which complements our innovation lab, enables us to directly control our manufacturing and product development efforts, and increases our speed-to-market. At the same time, we continued to gain market share in Breast Products, growing full year 2019 net sales by 25% over 2018 through continued strong growth in cosmetic procedures and record growth in our tissue expander business. In addition, we had a record year in our miraDry segment, which grew full year 2019 net sales by 20% over 2018, reflecting record system placements in North America and continued growth in bioTips utilization, as well as our targeted, cost-effective global marketing campaign."

Mr. Nugent added, "We remain focused on strengthening our balance sheet and were pleased to announce today that we have raised $60 million through a convertible debt financing with Deerfield Management. This infusion of capital provides us with enhanced financial flexibility to execute on our strategic initiatives as we continue on our path to aesthetics market leadership."

Mr. Nugent concluded, "Looking ahead, we remain focused on driving growth in net sales and profitability by continuing to gain market share in Breast Products, leveraging the significant brand value of miraDry, executing on our operational efficiency initiatives and realizing the full benefits of our OPUS implant manufacturing acquisition. I am confident our recent achievements, well-capitalized balance sheet, talented team and commitment to innovation will drive significant value for our shareholders and other stakeholders in 2020 and beyond."

Fourth Quarter and Full Year 2019 Financial Review

Total net sales for the fourth quarter 2019 were $23.2 million, an increase of 22% compared to total net sales of $19.0 million for the same period in 2018. Total net sales for full year 2019 were $83.7 million, an increase of 23% compared to total net sales of $68.1 million for full year 2018.

Net sales for the Breast Products segment totaled $12.8 million in the fourth quarter 2019, a 22% increase compared to $10.4 million for the same period in 2018. Net sales for the Breast Products segment in full year 2019 totaled $46.4 million, representing a 25% increase compared to $37.0 million in full year 2018. Breast Products sales growth was primarily driven by continued market share growth resulting from the Company's new customer conversion programs and deeper penetration of existing accounts.

Net sales for the miraDry segment totaled $10.4 million in the fourth quarter 2019, a 22% increase compared to $8.6 million for the same period in 2018. Net sales for the miraDry segment in full year 2019 totaled $37.3 million, representing a 20% increase compared to $31.1 million in full year 2018. miraDry sales growth was driven by continued momentum in both systems placements and consumables utilization, as well as the Company's cost-effective global marketing and brand awareness initiatives, which led to more than 2.7 million visits to miraDry.com and more than 100,000 new patient leads for providers in 2019.

Gross profit for the fourth quarter 2019 was $14.2 million, or 61.3% of sales, compared to gross profit of $11.4 million, or 59.7% of sales, for the same period in 2018. Gross profit for the full year 2019 was $50.7 million, or 60.6% of sales, compared to gross profit of $41.3 million, or 60.6% of sales, for full year 2018.

With respect to Sientra's organizational efficiency initiative, the Company remains on track to reduce annual pre-tax operating expenses by approximately $10 million in 2020 and another $5 million in 2021. Sientra is in the process of closing miraDry's Santa Clara facility, outsourcing miraDry product assembly and consolidating a number of business support functions at Sientra's Santa Barbara headquarters.

Excluding $1.1 million of restructuring charges related to Sientra's organizational efficiency initiative, operating expenses for the fourth quarter 2019 were $32.4 million, compared to $35.7 million of operating expenses for the same period in 2018.

Net loss for the fourth quarter 2019 was ($20.2) million, or ($0.41) per share, compared to a net loss of ($24.6) million, or ($0.86) per share, for the same period in 2018. Net loss for the full year of 2019 was ($106.8) million, or ($2.63) per share, compared to a net loss of ($82.6) million, or ($3.25) per share, for full year 2018.

On a non-GAAP basis, the Company reported an adjusted EBITDA loss of ($14.0) million and ($72.8) million for the fourth quarter and full year 2019, respectively, compared to a loss of ($19.4) million and ($60.0) million for the fourth quarter and full year 2018, respectively.

Net cash and cash equivalents as of December 31, 2019 were $88 million, compared to $121 million as of September 30, 2019. Uses of cash in the quarter included a $14 million upfront payment for the Vesta manufacturing operations to Lubrizol Life Science and $5 million of working capital investments associated with the acquisition of the OPUS manufacturing operation. Subsequent to year-end and as announced on March 11, 2020, Sientra completed a $60 million convertible financing with Deerfield Management.

2020 Net Sales Outlook

For full year 2020, the Company expects to achieve total net sales of $94 million to $98 million, representing growth of 12% to 17% compared to net sales of $83.7 million in 2019.

-- Breast Products net sales of $55 to $57 million; and

-- miraDry net sales of $39 to $41 million.

The current 2020 net sales outlook factors in anticipated impact from COVID-19. There is a significant level of uncertainty with this dynamic and evolving situation, and the Company will provide a financial and operational update if its 2020 outlook changes.

Conference Call

Sientra will hold a conference call today, March 11, 2020 at 5:00 pm ET to discuss fourth quarter results. The dial-in numbers are 844-464-3933 for domestic callers and 765-507-2612 for international callers. The conference ID is 9744698. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at www.sientra.com. The webcast will be archived on the website following the completion of the call.

Use of Non-GAAP Financial Measures

Sientra has supplemented its US GAAP net income (loss) with a non-GAAP measure of Adjusted EBITDA. Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the Company, facilitates a more meaningful comparison of results for current periods with previous operating results, and assists management in analyzing future trends, making strategic and business decisions and establishing internal budgets and forecasts. A reconciliation of non-GAAP Adjusted EBITDA to GAAP net income (loss), the most directly comparable GAAP measure, is provided in the schedule below.

There are limitations in using this non-GAAP financial measure because it is not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. This non-GAAP financial measure should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with Sientra's financial statements prepared in accordance with GAAP and the reconciliations of the non-GAAP financial measure provided in the schedule below.

About Sientra

Headquartered in Santa Barbara, California, Sientra is a diversified global medical aesthetics company and a leading partner to aesthetic physicians. The Company offers a suite of products designed to make a difference in patients' lives by enhancing their body image, growing their self-esteem, and restoring their confidence. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company's Breast Products Segment includes its OPUS breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2 breast tissue expander with patented dual-port and integral drain technology, and BIOCORNEUM the #1 performing, preferred and recommended scar gel of plastic surgeons. The Company's miraDry Segment, comprises its miraDry system, which is approved for sale in over 40 international markets, and is the only non-surgical FDA-cleared device for the permanent reduction of underarm sweat, odor and hair of all colors.

Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company's investor relations website at www.sientra.com.

Data on file

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are made only as of the date of this release. The words ''believe,'' ''may,'' ''might,'' ''could,'' ''will,'' ''aim,'' ''estimate,'' ''continue, ''anticipate,'' ''intend,'' ''expect,'' ''plan,'' ''position," or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Forward-looking statements may include information concerning the Company's possible or assumed future results of operations, including descriptions of the Company's revenues, profitability, outlook and overall business strategy. Such statements are subject to risks and uncertainties, including the positive reaction from plastic surgeons and their patients to Sientra's Breast Products, the ability to meet consumer demand, the acceptance and growth of its miraDry segment, and the Company's ability to realize the expected benefits of its organizational efficiency initiative. Additional factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Sientra's public filings with the Securities and Exchange Commission. All statements other than statements of historical fact are forward-looking statements. The words ''believe,'' ''may,'' ''might,'' ''could,'' ''will,'' ''aim,'' ''estimate,'' ''continue, ''anticipate,'' ''intend,'' ''expect,'' ''plan,'' ''position," or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, and such estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the Company's business.

Sientra, Inc
Consolidated Statements of Operations
(In thousands, except per share and share amounts)
(Unaudited)
                                                                                                             Three Months Ended                      Year Ended
                                                                                                             December 31,                            December 31,
                                                                                                             2019                2018                2019                2018
Net sales                                                                                                    $   23,210          $   19,022          $   83,699          $   68,126
Cost of goods sold                                                                                               8,971               7,668               33,012              26,822
Gross profit                                                                                                     14,239              11,354              50,687              41,304
Operating expenses:
Sales and marketing                                                                                              19,202              21,725              80,189              67,715
Research and development                                                                                         4,011               3,015               13,537              10,945
General and administrative                                                                                       9,233               10,999              46,771              42,418
Restructuring                                                                                                    1,083               --                  1,083               --
Goodwill and other intangible impairment                                                                         --                  --                  12,674              --
Total operating expenses                                                                                         33,529              35,739              154,254             121,078
Loss from operations                                                                                             (19,290    )        (24,385    )        (103,567   )        (79,774    )
Other income (expense), net:
Interest income                                                                                                  323                 318                 1,406               532
Interest expense                                                                                                 (1,292     )        (954       )        (4,568     )        (3,428     )
Other income (expense), net                                                                                      46                  386                 (55        )        39
Total other income (expense), net                                                                                (923       )        (250       )        (3,217     )        (2,857     )
Loss before income taxes                                                                                         (20,213    )        (24,635    )        (106,784   )        (82,631    )
Income tax (benefit) expense                                                                                     34                  (4         )        34                  (4         )
Net loss                                                                                                     $   (20,247    )    $   (24,631    )    $   (106,818   )    $   (82,627    )
Basic and diluted net loss per share attributable to common stockholders                                     $   (0.41      )    $   (0.86      )    $   (2.63      )    $   (3.25      )
Weighted average outstanding common shares used for net loss per share attributable to common stockholders:
Basic and diluted                                                                                                49,506,169          28,623,232          40,654,272          25,402,241
Sientra, Inc
Condensed Consolidated Balance Sheets
(In thousands)
(Unaudited)
                                                  December 31,     December 31,
                                                  2019             2018
Assets
Current assets:
Cash and cash equivalents                         $      87,608    $      86,899
Accounts receivable, net                                 27,548           22,527
Inventories, net                                         39,612           24,085
Prepaid expenses and other current assets                2,489            2,612
Total current assets                                     157,257          136,123
Property and equipment, net                              12,314           2,536
Goodwill                                                 9,202            12,507
Other intangible assets, net                             17,390           16,495
Other assets                                             8,241            698
Total assets                                      $      204,404   $      168,359
Liabilities and Stockholders' Equity
Current liabilities:
Current portion of long-term debt                 $      6,508     $      6,866
Accounts payable                                         9,352            13,184
Accrued and other current liabilities                    32,551           27,697
Legal settlement payable                                 --               410
Customer deposits                                        13,943           9,936
Sales return liability                                   8,116            6,048
Total current liabilities                                70,470           64,141
Long-term debt, net of current portion                   38,248           27,883
Deferred and contingent consideration                    5,177            6,481
Warranty reserve and other long-term liabilities         8,627            2,976
Total liabilities                                        122,522          101,481
Stockholders' equity:
Total stockholders' equity                               81,882           66,878
Total liabilities and stockholders' equity        $      204,404   $      168,359
Sientra, Inc
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
                                                                                                  Year Ended December 31,
                                                                                                  2019              2018
Cash flows from operating activities:
Net loss                                                                                          $     (106,818 )  $     (82,627 )
Adjustments to reconcile net loss to net cash used in operating activities:
Goodwill impairment                                                                                     7,629             --
Intangible asset impairment                                                                             5,045             --
Depreciation and amortization                                                                           3,524             3,321
Provision for doubtful accounts                                                                         2,298             2,043
Provision for warranties                                                                                929               325
Provision for inventory                                                                                 2,626             955
Amortization of right-of-use assets                                                                     4,174             --
Lease liability accretion                                                                               1,627             --
Change in fair value of warrants                                                                        (75      )        (81     )
Change in fair value of deferred consideration                                                          100               24
Change in fair value of contingent consideration                                                        1,044             2,528
Change in deferred revenue                                                                              1,124             627
Non-cash portion of debt extinguishment loss                                                            53                --
Amortization of debt discount and issuance costs                                                        359               174
Stock-based compensation expense                                                                        12,478            13,824
Loss on disposal of property and equipment                                                              119               74
Deferred income taxes                                                                                   18                (8      )
Payments of contingent consideration liability in excess of acquisition-date fair value                 (1,968   )        (320    )
Restructuring charges                                                                                   1,083             --
Changes in assets and liabilities:
Accounts receivable                                                                                     (7,320   )        (14,094 )
Inventories                                                                                             (10,921  )        (4,144  )
Prepaid expenses, other current assets and other assets                                                 (11,102  )        (1,302  )
Insurance recovery receivable                                                                           --                39
Accounts payable                                                                                        (2,225   )        8,502
Accrued and other liabilities                                                                           3,500             7,885
Legal settlement payable                                                                                (410     )        (590    )
Customer deposits                                                                                       4,008             4,513
Sales return liability                                                                                  2,068             2,142
Net cash used in operating activities                                                                   (87,033  )        (56,190 )
Cash flows from investing activities:
Purchase of property and equipment                                                                      (4,071   )        (855    )
Business acquisitions, net of cash and restricted cash acquired                                         (17,943  )        --
Net cash used in investing activities                                                                   (22,014  )        (855    )
Cash flows from financing activities:
Net proceeds from issuance of common stock                                                              107,734           107,551
Proceeds from exercise of stock options                                                                 125               1,149
Proceeds from issuance of common stock under ESPP                                                       1,216             993
Tax payments related to shares withheld for vested restricted stock units (RSUs)                        (3,064   )        (1,635  )
Gross borrowings under the Term Loan                                                                    5,000             10,000
Gross borrowings under the Revolving Loan                                                               22,296            12,109
Repayment of the Revolving Loan                                                                         (15,788  )        (12,109 )
Payments of contingent consideration up to acquisition-date fair value                                  (5,766   )        (680    )
Deferred financing costs                                                                                (1,997   )        (22     )
Net cash provided by financing activities                                                               109,756           117,356
Net increase in cash, cash equivalents and restricted cash                                              709               60,311
Cash, cash equivalents and restricted cash at:
Beginning of period                                                                                     87,242            26,931
End of period                                                                                     $     87,951      $     87,242
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets
Cash and cash equivalents                                                                         $     87,608      $     86,899
Restricted cash included in other assets                                                                343               343
Total cash, cash equivalents and restricted cash                                                  $     87,951      $     87,242
Sientra, Inc.
Reconciliation of Net Loss to Non-GAAP Adjusted EBITDA
(Unaudited)
                                                                 Three Months Ended                Year Ended
                                                                 December 31,                      December 31,
Dollars, in thousands                                            2019             2018             2019              2018
Net loss, as reported                                            $   (20,247 )    $   (24,631 )    $   (106,818 )    $   (82,627 )
Adjustments to net loss:
Interest (income) expense and other, net                             923              250              3,217             2,857
Provision for income taxes                                           34               (4      )        34                (4      )
Depreciation and amortization                                        986              821              3,524             3,427
Accretion in fair value adjustments to contingent consideration      454              368              1,044             2,528
Stock-based compensation                                             2,797            3,748            12,478            13,824
Restructuring                                                        1,083            --               1,083             --
Goodwill and other intangible impairment                             --               --               12,674            --
Total adjustments to net loss                                        6,277            5,183            34,054            22,632
Adjusted EBITDA                                                  $   (13,970 )    $   (19,448 )    $   (72,764  )    $   (59,995 )
                                                                 Three Months Ended                Year Ended
                                                                 December 31,                      December 31,
As a Percentage of Revenue**                                     2019             2018             2019              2018
Net loss, as reported                                                (87.2   %)       (129.5  %)       (127.6   %)       (121.3  %)
Adjustments to net loss:
Interest (income) expense and other, net                             4.0     %        1.3     %        3.8      %        4.2     %
Provision for income taxes                                           0.1     %        0.0     %        0.0      %        0.0     %
Depreciation and amortization                                        4.2     %        4.3     %        4.2      %        5.0     %
Accretion in fair value adjustments to contingent consideration      2.0     %        1.9     %        1.2      %        3.7     %
Stock-based compensation                                             12.1    %        19.7    %        14.9     %        20.3    %
Restructuring                                                        4.7     %        0.0     %        1.3      %        0.0     %
Goodwill and other intangible impairment                             0.0     %        0.0     %        15.1     %        0.0     %
Total adjustments to net loss                                        27.0    %        27.2    %        40.7     %        33.2    %
Adjusted EBITDA                                                      (60.2   %)       (102.2  %)       (86.9    %)       (88.1   %)
** Adjustments may not add to the total figure due to rounding
Contact
Investor Relations
805-679-8885

https://ml.globenewswire.com/media/3d42c3fa-0850-4a26-bd85-40bafedbaecd/small/logo-no-tag-2c-jpg.jpg

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.